Glioblastoma — frontier options in Ohio
30 open options
- TRIALPHASE2RECRUITING
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
ACT001 — 20 sites
- TRIALPHASE2RECRUITING
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Temozolomide · Neratinib · QBS10072S — 12 sites
- TRIALPHASE1 / PHASE2RECRUITING
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
TNG456 · abemaciclib — 15 sites
- TRIALPHASE4RECRUITING
Dabrafenib and/or Trametinib Rollover Study
dabrafenib · trametinib — 33 sites
- TRIALPHASE1 / PHASE2RECRUITING
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
TGX-007 · Valaciclovir — 2 sites
- TRIALPHASE1RECRUITING
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
Anti-GARP Chimeric Antigen Receptor-T Cells · Biospecimen Collection · Chest Radiography — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Biopsy Procedure · Magnetic Resonance Imaging · Radiation Therapy — 127 sites
- TRIALPHASE3RECRUITING
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
SonoCloud-9 (SC9) · Carboplatin · Lomustine — 55 sites
- TRIALPHASE2RECRUITING
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
DOC1021 · Tumor resection · Temodar (Temozolomide) — 18 sites
- TRIALPHASE1NOT_YET_RECRUITING
Study of Disulfiram to Reduce Myeloid Immunosuppression and Steroid Dependence in Resectable High Grade Glioma
Disulfiram (DSF) — 1 site
- TRIALNANOT_YET_RECRUITING
Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma
NaviFUS System · Lumason · Bevacizumab — 1 site
- TRIALPHASE2RECRUITING
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
PEP-CMV · Temozolomide · Tetanus Diphtheria Vaccine — 13 sites
- TRIALPHASE1RECRUITING
Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
Standard Surgical Treatment · Intraoperative Electrocorticography — 1 site
- TRIALEARLY_PHASE1RECRUITING
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
Larotrectinib · Larotrectinib surgical — 21 sites
- TRIALPHASE2RECRUITING
Sacituzumab Govitecan in Recurrent Glioblastoma
Sacituzumab Govitecan — 3 sites
- TRIALPHASE2RECRUITING
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
5-ALA HCl + LIDU SDT · Placebo + Sham SDT — 11 sites
- TRIALPHASE1NOT_YET_RECRUITING
Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency
Pembrolizumab · Navifus Focused Ultrasound Sonification — 1 site
- TRIALNARECRUITING
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
Device :DaRT seeds — 3 sites
- TRIALPHASE1RECRUITING
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Eflornithine (Dose Level 1) · Eflornithine (Dose Level 2) · Eflornithine (Dose Level -1) — 8 sites
- EXPANDED ACCESSAVAILABLE
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Ulixertinib (BVD-523) — 26 sites
- TRIALPHASE2RECRUITING
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
P140K-MGMT · O6-benzylguanine · Photon Based Radiotherapy — 1 site
- TRIALPHASE1RECRUITING
Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
NK cells — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Biospecimen Collection · Magnetic Resonance Imaging · Placebo Administration — 36 sites
- TRIALNANOT_YET_RECRUITING
Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-Being
Group Self-Management Sessions · Educational Materials Only — 2 sites
- TRIALPHASE2RECRUITING
Study of Olutasidenib and Temozolomide in HGG
Olutasidenib + TMZ — 20 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Oral repotrectinib (TPX-0005) — 68 sites
- TRIALPHASE2RECRUITING
A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
Sitagliptin — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
LUTATHERA® (Lutetium Lu 177 dotatate) — 4 sites
- TRIALPHASE3RECRUITING
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Optune® device · Temozolomide · Pembrolizumab — 102 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Temozolomide · Lomustine · Regorafenib — 63 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.